Your browser doesn't support javascript.
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain.
Miller, Nathaniel L; Clark, Thomas; Raman, Rahul; Sasisekharan, Ram.
  • Miller NL; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Clark T; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Raman R; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Sasisekharan R; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Cell Rep Med ; 3(2): 100527, 2022 02 15.
Article in English | MEDLINE | ID: covidwho-1649678
ABSTRACT
The Omicron variant features enhanced transmissibility and antibody escape. Here, we describe the Omicron receptor-binding domain (RBD) mutational landscape using amino acid interaction (AAI) networks, which are well suited for interrogating constellations of mutations that function in an epistatic manner. Using AAI, we map Omicron mutations directly and indirectly driving increased escape breadth and depth in class 1-4 antibody epitopes. Further, we present epitope networks for authorized therapeutic antibodies and assess perturbations to each antibody's epitope. Since our initial modeling following the identification of Omicron, these predictions have been realized by experimental findings of Omicron neutralization escape from therapeutic antibodies ADG20, AZD8895, and AZD1061. Importantly, the AAI predicted escape resulting from indirect epitope perturbations was not captured by previous sequence or point mutation analyses. Finally, for several Omicron RBD mutations, we find evidence for a plausible role in enhanced transmissibility via disruption of RBD-down conformational stability at the RBDdown-RBDdown interface.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Protein Domains / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral / Mutation Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100527

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Protein Domains / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral / Mutation Type of study: Prognostic study Topics: Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article Affiliation country: J.xcrm.2022.100527